• Home
  • Inside Kyverna
  • The Science
  • Our Opportunity
  • News
  • Careers
  • Contact
Kyverna Therapeutics

News & Events

Press Releases

January 26, 2022

Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures

January 5, 2022

Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

January 3, 2022

Kyverna Therapeutics Announces Exclusive Worldwide Licenses With National Institutes of Health for Autologous and Allogeneic Anti-CD19 CAR T Cellular Therapies to Treat Autoimmune Diseases

September 15, 2021

Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer

April 13, 2021

Kyverna Therapeutics Announces the Appointment of James Chung, M.D., Ph.D., as Chief Medical Officer

January 13, 2020

Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences

Media Inquiries

To learn more about Kyverna’s work developing cell therapies for inflammatory and autoimmune disease, please reach out to us at:

media@kyvernatx.com
kyverna_logo_inv

Links

  • Home
  • News
  • Inside Kyverna
  • Careers
  • The Science
  • Contact
  • Our Opportunity

About

Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress or eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. In addition to developing next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic settings, Kyverna is creating synReg T cells, a synthetic version of Regulatory T cells (Tregs), powerful natural immune cells that control immune homeostasis through multiple immunosuppressive mechanisms. By offering more than one mechanism for taming autoimmunity, Kyverna is positioned to transform how autoimmune diseases are treated.

FOLLOW US ON SOCIAL

©2022 Kyverna Therapeutics, Inc. All rights reserved.
  • Privacy Policy